Progyny Inc (NASDAQ:PGNY) Director Norman Payson sold 16,500 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $26.07, for a total value of $430,155.00. Following the completion of the transaction, the director now owns 522,446 shares of the company’s stock, valued at approximately $13,620,167.22. The sale was disclosed in a document filed with the SEC, which is available through this link.

Norman Payson also recently made the following trade(s):

  • On Wednesday, July 22nd, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $25.69, for a total value of $423,885.00.
  • On Wednesday, July 15th, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $25.47, for a total value of $420,255.00.
  • On Wednesday, July 8th, Norman Payson sold 16,500 shares of Progyny stock. The shares were sold at an average price of $25.79, for a total value of $425,535.00.
  • On Tuesday, June 30th, Norman Payson sold 16,500 shares of Progyny stock. The stock was sold at an average price of $25.55, for a total value of $421,575.00.
  • On Wednesday, June 24th, Norman Payson sold 16,500 shares of Progyny stock. The stock was sold at an average price of $25.65, for a total value of $423,225.00.
  • On Thursday, June 18th, Norman Payson sold 33,000 shares of Progyny stock. The stock was sold at an average price of $22.87, for a total value of $754,710.00.
  • On Thursday, June 11th, Norman Payson sold 33,200 shares of Progyny stock. The stock was sold at an average price of $22.56, for a total value of $748,992.00.
  • On Wednesday, June 3rd, Norman Payson sold 17,000 shares of Progyny stock. The stock was sold at an average price of $24.47, for a total value of $415,990.00.
  • On Wednesday, May 27th, Norman Payson sold 17,000 shares of Progyny stock. The stock was sold at an average price of $24.28, for a total value of $412,760.00.
  • On Wednesday, May 20th, Norman Payson sold 17,000 shares of Progyny stock. The stock was sold at an average price of $25.59, for a total value of $435,030.00.

Shares of PGNY stock opened at $26.63 on Friday. Progyny Inc has a 12-month low of $13.29 and a 12-month high of $36.50. The firm has a 50 day moving average price of $25.34 and a two-hundred day moving average price of $25.30.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $81.02 million during the quarter, compared to analyst estimates of $71.81 million. The company’s revenue for the quarter was up 71.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Progyny Inc will post 0.17 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG raised its position in shares of Progyny by 294.3% in the second quarter. UBS Group AG now owns 21,858 shares of the company’s stock valued at $564,000 after buying an additional 16,315 shares in the last quarter. Roubaix Capital LLC acquired a new stake in shares of Progyny in the second quarter valued at approximately $2,994,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Progyny in the second quarter valued at approximately $96,000. Strs Ohio acquired a new stake in shares of Progyny in the second quarter valued at approximately $2,191,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Progyny in the second quarter valued at approximately $1,971,000. Institutional investors own 38.04% of the company’s stock.

A number of equities analysts recently commented on the company. Guggenheim assumed coverage on Progyny in a report on Tuesday, June 2nd. They set a “buy” rating and a $30.00 price target for the company. SVB Leerink initiated coverage on shares of Progyny in a research report on Wednesday, July 1st. They set an “outperform” rating and a $35.00 price objective for the company. Citigroup cut their price objective on shares of Progyny from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Bank of America raised their price objective on shares of Progyny from $26.00 to $28.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Zacks Investment Research upgraded shares of Progyny from a “sell” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $29.63.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.